(Q46979383)

27 December 2017

title

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation (English)

1 reference

27 December 2017

non-small-cell lung carcinoma

1 reference

1 reference

Minggui Pan

1

1 reference

27 December 2017

Monica Santamaria

series ordinal

2

1 reference

27 December 2017

David B Wollman

series ordinal

3

1 reference

27 December 2017

publication date

1 October 2007

1 reference

27 December 2017

Nature Clinical Practice Oncology

published in

1 reference

27 December 2017

volume

4

1 reference

27 December 2017

issue

10

1 reference

27 December 2017

page(s)

603-607

1 reference

27 December 2017

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0931

7 January 2021

Identifiers

DOI

10.1038/NCPONC0931

1 reference

27 December 2017

1 reference

27 December 2017